... the biopharmaceutical company's stock worth $100,000 after acquiring an additional 140 shares in the last quarter. Ardsley Advisory Partners boosted its stake in CymaBay Therapeutics by 66.2% during the second quarter. Ardsley Advisory Partners now ...
http://ift.tt/2Bnn8zB
No comments:
Post a Comment